This inventor holds 5 USPTO granted patents. Top assignees: Astra Lakemedel Aktiebolag, Per Arvid Emil Carlsson, Other. Active years: 1984-1994.
Location History:
- Gothenburg, SE (1988)
- Gothenborg, SE (1989)
- Goteborg, SE (1984 - 1994)
Company Filing History:
1 out of 68 
1 out of 1 
3 out of 834,453 Years Active: 1984-1994
Title: The Innovations of John S Hjorth
Introduction
John S Hjorth is a notable inventor based in Goteborg, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for therapeutic purposes. With a total of 5 patents, Hjorth's work focuses on addressing disorders in the central nervous system.
Latest Patents
Hjorth's latest patents include innovative compounds such as 1-alkyl-2-aminotetralin derivatives. These compounds are characterized by a specific formula where R³ and the NR¹ R² group are in a cis-position to each other. The compounds are designed for therapeutic applications, especially in treating central nervous system disorders. Another significant patent involves phenyl-azacykloalkanes, which also serve therapeutic purposes. These compounds are formulated to aid in the treatment of various disorders affecting the central nervous system.
Career Highlights
Throughout his career, John S Hjorth has worked with prominent companies, including Per Arvid Emil Carlsson. His experience in the pharmaceutical industry has allowed him to develop groundbreaking compounds that have the potential to improve patient outcomes.
Collaborations
Hjorth has collaborated with notable individuals in his field, including Folke L Arvidsson and Per A Carlsson. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
John S Hjorth's contributions to pharmaceutical innovations highlight his dedication to improving therapeutic treatments for central nervous system disorders. His patents reflect a commitment to advancing medical science and enhancing patient care.